Cargando…

Proteomic research in sarcomas – current status and future opportunities

Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Jessica, Wilding, Christopher P, L Jones, Robin, H Huang, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083238/
https://www.ncbi.nlm.nih.gov/pubmed/31722230
http://dx.doi.org/10.1016/j.semcancer.2019.11.003
_version_ 1783508495398600704
author Burns, Jessica
Wilding, Christopher P
L Jones, Robin
H Huang, Paul
author_facet Burns, Jessica
Wilding, Christopher P
L Jones, Robin
H Huang, Paul
author_sort Burns, Jessica
collection PubMed
description Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regimens have been made over the past few decades. Proteomics techniques are being increasingly utilised in the field of sarcoma research. Proteomic research efforts have thus far focused on histological subtype characterisation for the improvement of biological understanding, as well as for the identification of candidate diagnostic, predictive, and prognostic biomarkers for use in clinic. However, the field itself is in its infancy, and none of these proteomic research findings have been translated into the clinic. In this review, we provide a brief overview of the proteomic strategies that have been employed in sarcoma research. We evaluate key proteomic studies concerning several rare and ultra-rare sarcoma subtypes including, gastrointestinal stromal tumours, osteosarcoma, liposarcoma, leiomyosarcoma, malignant rhabdoid tumours, Ewing sarcoma, myxofibrosarcoma, and alveolar soft part sarcoma. Consequently, we illustrate how routine implementation of proteomics within sarcoma research, integration of proteomics with other molecular profiling data, and incorporation of proteomics into clinical trial studies has the potential to propel the biological and clinical understanding of this group of complex rare cancers moving forward.
format Online
Article
Text
id pubmed-7083238
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-70832382020-04-01 Proteomic research in sarcomas – current status and future opportunities Burns, Jessica Wilding, Christopher P L Jones, Robin H Huang, Paul Semin Cancer Biol Article Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regimens have been made over the past few decades. Proteomics techniques are being increasingly utilised in the field of sarcoma research. Proteomic research efforts have thus far focused on histological subtype characterisation for the improvement of biological understanding, as well as for the identification of candidate diagnostic, predictive, and prognostic biomarkers for use in clinic. However, the field itself is in its infancy, and none of these proteomic research findings have been translated into the clinic. In this review, we provide a brief overview of the proteomic strategies that have been employed in sarcoma research. We evaluate key proteomic studies concerning several rare and ultra-rare sarcoma subtypes including, gastrointestinal stromal tumours, osteosarcoma, liposarcoma, leiomyosarcoma, malignant rhabdoid tumours, Ewing sarcoma, myxofibrosarcoma, and alveolar soft part sarcoma. Consequently, we illustrate how routine implementation of proteomics within sarcoma research, integration of proteomics with other molecular profiling data, and incorporation of proteomics into clinical trial studies has the potential to propel the biological and clinical understanding of this group of complex rare cancers moving forward. Academic Press 2020-04 /pmc/articles/PMC7083238/ /pubmed/31722230 http://dx.doi.org/10.1016/j.semcancer.2019.11.003 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Burns, Jessica
Wilding, Christopher P
L Jones, Robin
H Huang, Paul
Proteomic research in sarcomas – current status and future opportunities
title Proteomic research in sarcomas – current status and future opportunities
title_full Proteomic research in sarcomas – current status and future opportunities
title_fullStr Proteomic research in sarcomas – current status and future opportunities
title_full_unstemmed Proteomic research in sarcomas – current status and future opportunities
title_short Proteomic research in sarcomas – current status and future opportunities
title_sort proteomic research in sarcomas – current status and future opportunities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083238/
https://www.ncbi.nlm.nih.gov/pubmed/31722230
http://dx.doi.org/10.1016/j.semcancer.2019.11.003
work_keys_str_mv AT burnsjessica proteomicresearchinsarcomascurrentstatusandfutureopportunities
AT wildingchristopherp proteomicresearchinsarcomascurrentstatusandfutureopportunities
AT ljonesrobin proteomicresearchinsarcomascurrentstatusandfutureopportunities
AT hhuangpaul proteomicresearchinsarcomascurrentstatusandfutureopportunities